CALABRESI, LAURA
 Distribuzione geografica
Continente #
NA - Nord America 818
EU - Europa 700
AS - Asia 233
SA - Sud America 12
OC - Oceania 7
AF - Africa 4
Totale 1.774
Nazione #
US - Stati Uniti d'America 815
PL - Polonia 220
RU - Federazione Russa 216
IT - Italia 103
SG - Singapore 79
HK - Hong Kong 76
IE - Irlanda 48
CN - Cina 37
SE - Svezia 35
CH - Svizzera 30
DE - Germania 13
BR - Brasile 12
GB - Regno Unito 11
JO - Giordania 11
IN - India 8
AU - Australia 7
FI - Finlandia 6
FR - Francia 6
ID - Indonesia 6
VN - Vietnam 6
KR - Corea 5
BE - Belgio 4
NL - Olanda 4
CA - Canada 3
CI - Costa d'Avorio 2
ES - Italia 2
JP - Giappone 2
UA - Ucraina 2
CY - Cipro 1
MU - Mauritius 1
PK - Pakistan 1
TN - Tunisia 1
UZ - Uzbekistan 1
Totale 1.774
Città #
Santa Clara 262
Warsaw 220
Fairfield 73
Hong Kong 68
Chandler 52
Dublin 48
Ashburn 40
Florence 38
Woodbridge 37
Singapore 36
Seattle 35
Houston 33
Ann Arbor 30
Cambridge 30
Bern 28
Wilmington 24
Altamura 14
Lawrence 14
Princeton 11
Beijing 10
Bremen 10
Buffalo 9
Los Angeles 9
Moscow 9
Boston 8
Mumbai 7
Dong Ket 6
Jakarta 6
Kent 6
Melbourne 6
New York 6
Dearborn 5
Shanghai 5
Brussels 4
Cagliari 4
San Diego 4
Seoul 4
Boardman 3
Hillsboro 3
Redwood City 3
San Jose 3
Yubileyny 3
Abidjan 2
Basel 2
Cantagallo 2
Cusano Milanino 2
Ealing 2
Edmonton 2
Falls Church 2
Fiesole 2
Hangzhou 2
Helsinki 2
Kunming 2
Medford 2
Phoenix 2
Reston 2
Romainville 2
Seville 2
São Paulo 2
Tokyo 2
Andover 1
Augusta 1
Barra do Piraí 1
Bethesda 1
Bom Jesus do Tocantins 1
Brasília 1
Béja 1
Corato 1
Dnipro 1
Faisalabad 1
Falkenstein 1
Fiumicino 1
Fontebuona 1
Goiânia 1
Harbin 1
Jacksonville 1
Langfang 1
Lappeenranta 1
Livorno 1
Milan 1
Monteroni D'arbia 1
Montreal 1
Munich 1
Nanchang 1
Nicosia 1
Noisy-le-sec 1
Nova Serrana 1
Pelotas 1
Perth 1
Pisa 1
Porto Ferreira 1
Pune 1
Resende 1
Rome 1
Salerno 1
Salvador 1
Scarperia e San Piero 1
Schiavon 1
Shenzhen 1
Signa 1
Totale 1.302
Nome #
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 285
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis 190
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants 186
Characterization of novel molecular targets and mechanisms in Philadelphia-negative Myeloproliferative Neoplasms 158
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 147
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 136
CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles 130
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature 118
Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs 94
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 89
The MPL mutation 75
Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model 62
Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms 56
Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells 40
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 32
Totale 1.798
Categoria #
all - tutte 5.429
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.429


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202066 0 0 0 0 0 0 0 0 23 13 25 5
2020/2021156 9 23 4 20 11 16 8 10 15 23 7 10
2021/202270 1 2 8 0 2 4 0 7 5 6 14 21
2022/2023268 15 51 14 22 15 34 30 14 29 2 9 33
2023/2024132 2 15 15 5 12 16 1 37 4 5 13 7
2024/2025725 27 72 44 131 212 128 18 41 52 0 0 0
Totale 1.798